Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Interleukin-6 (IL-6) (B-cell stimulatory factor 2) (BSF-2) (CTL differentiation factor) (CDF) (Hybridoma growth factor) (Interferon beta-2) (IFN-beta-2)

 IL6_HUMAN               Reviewed;         212 AA.
P05231; Q9UCU2; Q9UCU3; Q9UCU4;
13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
13-AUG-1987, sequence version 1.
30-AUG-2017, entry version 206.
RecName: Full=Interleukin-6;
Short=IL-6;
AltName: Full=B-cell stimulatory factor 2;
Short=BSF-2;
AltName: Full=CTL differentiation factor;
Short=CDF;
AltName: Full=Hybridoma growth factor;
AltName: Full=Interferon beta-2;
Short=IFN-beta-2;
Flags: Precursor;
Name=IL6; Synonyms=IFNB2;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
PubMed=3491322; DOI=10.1038/324073a0;
Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T.,
Kashiwamura S., Nakajima K., Koyama K., Iwamatsu A., Tsunasawa S.,
Sakiyama F., Matsui H., Takahara Y., Taniguchi T., Kishimoto T.;
"Complementary DNA for a novel human interleukin (BSF-2) that induces
B lymphocytes to produce immunoglobulin.";
Nature 324:73-76(1986).
[2]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
PubMed=3500852;
Yasukawa K., Hirano T., Watanabe Y., Muratani K., Matsuda T.,
Nakai S., Kishimoto T.;
"Structure and expression of human B cell stimulatory factor-2 (BSF-
2/IL-6) gene.";
EMBO J. 6:2939-2945(1987).
[3]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=3538015; DOI=10.1073/pnas.83.23.8957;
May L.T., Helfgott D.C., Sehgal P.B.;
"Anti-beta-interferon antibodies inhibit the increased expression of
HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts:
structural studies of the beta 2 interferon involved.";
Proc. Natl. Acad. Sci. U.S.A. 83:8957-8961(1986).
[4]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=3023045;
Zilberstein A., Ruggieri R., Korn J.H., Revel M.;
"Structure and expression of cDNA and genes for human interferon-beta-
2, a distinct species inducible by growth-stimulatory cytokines.";
EMBO J. 5:2529-2537(1986).
[5]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=3320204;
Brakenhoff J.P.J., de Groot E.R., Evers R.F., Pannekoek H.,
Aarden L.A.;
"Molecular cloning and expression of hybridoma growth factor in
Escherichia coli.";
J. Immunol. 139:4116-4121(1987).
[6]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=2789513; DOI=10.1016/0006-291X(89)92328-0;
Tonouchi N., Miwa K., Karasuyama H., Matsui H.;
"Deletion of 3' untranslated region of human BSF-2 mRNA causes
stabilization of the mRNA and high-level expression in mouse NIH3T3
cells.";
Biochem. Biophys. Res. Commun. 163:1056-1062(1989).
[7]
NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
TISSUE=Fibroblast;
PubMed=3758081; DOI=10.1111/j.1432-1033.1986.tb09931.x;
Haegeman G., Content J., Volckaert G., Derynck R., Tavernier J.,
Fiers W.;
"Structural analysis of the sequence coding for an inducible 26-kDa
protein in human fibroblasts.";
Eur. J. Biochem. 159:625-632(1986).
[8]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=3266463;
Wong G., Witek-Giannotti J., Hewick R., Clark S., Ogawa M.;
"Interleukin 6: identification as a hematopoietic colony-stimulating
factor.";
Behring Inst. Mitt. 83:40-47(1988).
[9]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=1291290;
Chen Q.Y.;
"Stable and efficient expression of human interleukin-6 cDNA in
mammalian cells after gene transfer.";
Zhonghua Zhong Liu Za Zhi 14:340-344(1992).
[10]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-32 AND VAL-162.
SeattleSNPs variation discovery resource;
Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
[11]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
TISSUE=Lung;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[12]
PROTEIN SEQUENCE OF 30-63.
PubMed=3279116;
van Damme J., van Beeumen J., Decock B., van Snick J., de Ley M.,
Billiau A.;
"Separation and comparison of two monokines with lymphocyte-activating
factor activity: IL-1 beta and hybridoma growth factor (HGF).
Identification of leukocyte-derived HGF as IL-6.";
J. Immunol. 140:1534-1541(1988).
[13]
PROTEIN SEQUENCE OF 30-50.
PubMed=2610854;
Ming J.E., Cernetti C., Steinman R.M., Granelli-Piperno A.;
"Interleukin 6 is the principal cytolytic T lymphocyte differentiation
factor for thymocytes in human leukocyte conditioned medium.";
J. Mol. Cell. Immunol. 4:203-211(1989).
[14]
PROTEIN SEQUENCE OF 30-40, AND GLYCOSYLATION.
PubMed=1883960; DOI=10.1016/1043-4666(91)90018-9;
May L.T., Shaw J.E., Khanna A.K., Zabriskie J.B., Sehgal P.B.;
"Marked cell-type-specific differences in glycosylation of human
interleukin-6.";
Cytokine 3:204-211(1991).
[15]
PROTEIN SEQUENCE OF 50-212.
PubMed=7851440; DOI=10.1111/j.1432-1033.1995.tb20427.x;
Breton J., la Fiura A., Bertolero F., Orsini G., Valsasina B.,
Ziliotto R., de Filippis V., Polverino de Laureto P., Fontana A.;
"Structure, stability and biological properties of a N-terminally
truncated form of recombinant human interleukin-6 containing a single
disulfide bond.";
Eur. J. Biochem. 227:573-581(1995).
[16]
DISULFIDE BONDS.
PubMed=2472117; DOI=10.1016/0003-9861(89)90205-1;
Clogston C.L., Boone T.C., Crandall B.C., Mendiaz E.A., Lu H.S.;
"Disulfide structures of human interleukin-6 are similar to those of
human granulocyte colony stimulating factor.";
Arch. Biochem. Biophys. 272:144-151(1989).
[17]
MUTAGENESIS.
PubMed=2037043; DOI=10.1016/0014-5793(91)80491-K;
Luetticken C., Kruettgen A., Moeller C., Heinrich P.C., Rose-John S.;
"Evidence for the importance of a positive charge and an alpha-helical
structure of the C-terminus for biological activity of human IL-6.";
FEBS Lett. 282:265-267(1991).
[18]
STRUCTURE BY NMR.
PubMed=8555185; DOI=10.1021/bi951949e;
Nishimura C., Watanabe A., Gouda H., Shimada I., Arata Y.;
"Folding topologies of human interleukin-6 and its mutants as studied
by NMR spectroscopy.";
Biochemistry 35:273-281(1996).
[19]
STRUCTURE BY NMR.
PubMed=9159484; DOI=10.1006/jmbi.1997.0933;
Xu G.-Y., Yu H.-A., Hong J., Stahl M., McDonagh T., Kay L.E.,
Cumming D.A.;
"Solution structure of recombinant human interleukin-6.";
J. Mol. Biol. 268:468-481(1997).
[20]
X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
PubMed=9118960; DOI=10.1093/emboj/16.5.989;
Somers W., Stahl M., Seehra J.S.;
"1.9-A crystal structure of interleukin 6: implications for a novel
mode of receptor dimerization and signaling.";
EMBO J. 16:989-997(1997).
[21]
INVOLVEMENT IN RASJ.
PubMed=9769329; DOI=10.1172/JCI2629;
Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S.,
Humphries S., Woo P.;
"The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on
IL-6 transcription and plasma IL-6 levels, and an association with
systemic-onset juvenile chronic arthritis.";
J. Clin. Invest. 102:1369-1376(1998).
[22]
INVOLVEMENT IN SUSCEPTIBILITY TO KAPOSI SARCOMA.
PubMed=11001912;
Foster C.B., Lehrnbecher T., Samuels S., Stein S., Mol F.,
Metcalf J.A., Wyvill K., Steinberg S.M., Kovacs J., Blauvelt A.,
Yarchoan R., Chanock S.J.;
"An IL6 promoter polymorphism is associated with a lifetime risk of
development of Kaposi sarcoma in men infected with human
immunodeficiency virus.";
Blood 96:2562-2567(2000).
[23]
INVOLVEMENT IN BMD.
PubMed=11355017; DOI=10.1007/s100380170077;
Ota N., Nakajima T., Nakazawa I., Suzuki T., Hosoi T., Orimo H.,
Inoue S., Shirai Y., Emi M.;
"A nucleotide variant in the promoter region of the interleukin-6 gene
associated with decreased bone mineral density.";
J. Hum. Genet. 46:267-272(2001).
[24]
INVOLVEMENT IN BMD.
PubMed=12768442; DOI=10.1007/s10038-003-0020-8;
Chung H.W., Seo J.-S., Hur S.E., Kim H.L., Kim J.Y., Jung J.H.,
Kim L.H., Park B.L., Shin H.D.;
"Association of interleukin-6 promoter variant with bone mineral
density in pre-menopausal women.";
J. Hum. Genet. 48:243-248(2003).
[25]
PHOSPHORYLATION AT SER-81.
PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
Pinna L.A., Pagliarini D.J., Dixon J.E.;
"A single kinase generates the majority of the secreted
phosphoproteome.";
Cell 161:1619-1632(2015).
-!- FUNCTION: Cytokine with a wide variety of biological functions. It
is a potent inducer of the acute phase response. Plays an
essential role in the final differentiation of B-cells into Ig-
secreting cells Involved in lymphocyte and monocyte
differentiation. Acts on B-cells, T-cells, hepatocytes,
hematopoietic progenitor cells and cells of the CNS. Required for
the generation of T(H)17 cells. Also acts as a myokine. It is
discharged into the bloodstream after muscle contraction and acts
to increase the breakdown of fats and to improve insulin
resistance. It induces myeloma and plasmacytoma growth and induces
nerve cells differentiation.
-!- INTERACTION:
P08887:IL6R; NbExp=6; IntAct=EBI-720533, EBI-299383;
Q05516:ZBTB16; NbExp=2; IntAct=EBI-720533, EBI-711925;
-!- SUBCELLULAR LOCATION: Secreted.
-!- PTM: N- and O-glycosylated. {ECO:0000269|PubMed:1883960}.
-!- POLYMORPHISM: Genetic variations in IL6 may be correlated with
bone mineral density (BMD). Low BMD is a risk factor for
osteoporotic fracture. Osteoporosis is characterized by reduced
bone mineral density, disruption of bone microarchitecture, and
the alteration of the amount and variety of non-collagenous
proteins in bone. Osteoporotic bones are more at risk of fracture.
{ECO:0000269|PubMed:11355017, ECO:0000269|PubMed:12768442}.
-!- DISEASE: Rheumatoid arthritis systemic juvenile (RASJ)
[MIM:604302]: An inflammatory articular disorder with systemic-
onset beginning before the age of 16. It represents a subgroup of
juvenile arthritis associated with severe extraarticular features
and occasionally fatal complications. During active phases of the
disorder, patients display a typical daily spiking fever, an
evanescent macular rash, lymphadenopathy, hepatosplenomegaly,
serositis, myalgia and arthritis. {ECO:0000269|PubMed:9769329}.
Note=Disease susceptibility is associated with variations
affecting the gene represented in this entry.
-!- DISEASE: Note=A IL6 promoter polymorphism is associated with a
lifetime risk of development of Kaposi sarcoma in HIV-infected
men. {ECO:0000269|PubMed:11001912}.
-!- SIMILARITY: Belongs to the IL-6 superfamily. {ECO:0000305}.
-!- WEB RESOURCE: Name=Wikipedia; Note=Interleukin-6 entry;
URL="https://en.wikipedia.org/wiki/Interleukin_6";
-!- WEB RESOURCE: Name=SeattleSNPs;
URL="http://pga.gs.washington.edu/data/il6/";
-!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
polymorphism database;
URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL6";
-!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
and Haematology;
URL="http://atlasgeneticsoncology.org/Genes/IL6ID519ch7p15.html";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; X04430; CAA28026.1; -; mRNA.
EMBL; M14584; AAA52728.1; -; mRNA.
EMBL; X04602; CAA28268.1; -; mRNA.
EMBL; Y00081; CAA68278.1; -; Genomic_DNA.
EMBL; M18403; AAA52729.1; -; mRNA.
EMBL; M29150; AAA59154.1; -; mRNA.
EMBL; X04402; CAA27990.1; -; Genomic_DNA.
EMBL; X04403; CAA27991.1; -; mRNA.
EMBL; M54894; AAC41704.1; -; mRNA.
EMBL; S56892; AAD13886.1; -; mRNA.
EMBL; AF372214; AAK48987.1; -; Genomic_DNA.
EMBL; BC015511; AAH15511.1; -; mRNA.
CCDS; CCDS5375.1; -.
PIR; A32648; IVHUB2.
RefSeq; NP_000591.1; NM_000600.4.
RefSeq; XP_011513692.1; XM_011515390.2.
UniGene; Hs.654458; -.
PDB; 1ALU; X-ray; 1.90 A; A=28-212.
PDB; 1IL6; NMR; -; A=28-212.
PDB; 1N2Q; Model; -; E/F=30-212.
PDB; 1P9M; X-ray; 3.65 A; B=29-212.
PDB; 2IL6; NMR; -; A=28-212.
PDB; 4CNI; X-ray; 2.20 A; C/D=42-212.
PDB; 4J4L; X-ray; 2.30 A; C/D=47-212.
PDB; 4NI7; X-ray; 2.40 A; A=28-212.
PDB; 4NI9; X-ray; 2.55 A; A/C=28-212.
PDB; 4O9H; X-ray; 2.42 A; A=28-212.
PDB; 4ZS7; X-ray; 2.93 A; A=42-212.
PDB; 5FUC; X-ray; 2.70 A; A/B=49-212.
PDBsum; 1ALU; -.
PDBsum; 1IL6; -.
PDBsum; 1N2Q; -.
PDBsum; 1P9M; -.
PDBsum; 2IL6; -.
PDBsum; 4CNI; -.
PDBsum; 4J4L; -.
PDBsum; 4NI7; -.
PDBsum; 4NI9; -.
PDBsum; 4O9H; -.
PDBsum; 4ZS7; -.
PDBsum; 5FUC; -.
ProteinModelPortal; P05231; -.
SMR; P05231; -.
BioGrid; 109783; 4.
DIP; DIP-482N; -.
IntAct; P05231; 6.
MINT; MINT-190042; -.
STRING; 9606.ENSP00000258743; -.
BindingDB; P05231; -.
ChEMBL; CHEMBL1795129; -.
DrugBank; DB05250; 681323.
DrugBank; DB05066; AV411.
DrugBank; DB05744; CRx-139.
DrugBank; DB01404; Ginseng.
DrugBank; DB05767; HMPL-004.
DrugBank; DB09036; Siltuximab.
DrugBank; DB05470; VX-702.
DrugBank; DB05017; YSIL6.
iPTMnet; P05231; -.
PhosphoSitePlus; P05231; -.
BioMuta; IL6; -.
DMDM; 124347; -.
EPD; P05231; -.
PaxDb; P05231; -.
PeptideAtlas; P05231; -.
PRIDE; P05231; -.
DNASU; 3569; -.
Ensembl; ENST00000258743; ENSP00000258743; ENSG00000136244.
Ensembl; ENST00000404625; ENSP00000385675; ENSG00000136244.
GeneID; 3569; -.
KEGG; hsa:3569; -.
CTD; 3569; -.
DisGeNET; 3569; -.
GeneCards; IL6; -.
H-InvDB; HIX0167872; -.
HGNC; HGNC:6018; IL6.
HPA; CAB023406; -.
HPA; CAB072821; -.
MalaCards; IL6; -.
MIM; 147620; gene.
MIM; 148000; phenotype.
MIM; 604302; phenotype.
neXtProt; NX_P05231; -.
OpenTargets; ENSG00000136244; -.
Orphanet; 206; Crohn disease.
Orphanet; 85414; Systemic-onset juvenile idiopathic arthritis.
PharmGKB; PA198; -.
eggNOG; ENOG410IW11; Eukaryota.
eggNOG; ENOG4112BXV; LUCA.
GeneTree; ENSGT00390000000878; -.
HOGENOM; HOG000236330; -.
HOVERGEN; HBG000471; -.
InParanoid; P05231; -.
KO; K05405; -.
OMA; LQAQNQW; -.
OrthoDB; EOG091G0NW5; -.
PhylomeDB; P05231; -.
TreeFam; TF335984; -.
Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
Reactome; R-HSA-6783589; Interleukin-6 family signaling.
Reactome; R-HSA-6783783; Interleukin-10 signaling.
Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
SignaLink; P05231; -.
SIGNOR; P05231; -.
ChiTaRS; IL6; human.
EvolutionaryTrace; P05231; -.
GeneWiki; Interleukin_6; -.
GenomeRNAi; 3569; -.
PMAP-CutDB; P05231; -.
PRO; PR:P05231; -.
Proteomes; UP000005640; Chromosome 7.
Bgee; ENSG00000136244; -.
CleanEx; HS_IL6; -.
ExpressionAtlas; P05231; baseline and differential.
Genevisible; P05231; HS.
GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
GO; GO:0005576; C:extracellular region; TAS:Reactome.
GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
GO; GO:0005896; C:interleukin-6 receptor complex; IDA:BHF-UCL.
GO; GO:0005125; F:cytokine activity; IDA:BHF-UCL.
GO; GO:0008083; F:growth factor activity; IDA:BHF-UCL.
GO; GO:0005138; F:interleukin-6 receptor binding; IPI:BHF-UCL.
GO; GO:0006953; P:acute-phase response; TAS:BHF-UCL.
GO; GO:0007568; P:aging; IEA:Ensembl.
GO; GO:0046849; P:bone remodeling; IEA:Ensembl.
GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IEA:Ensembl.
GO; GO:0016049; P:cell growth; IEA:Ensembl.
GO; GO:0045454; P:cell redox homeostasis; IEA:Ensembl.
GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
GO; GO:0071392; P:cellular response to estradiol stimulus; IEA:Ensembl.
GO; GO:0035729; P:cellular response to hepatocyte growth factor stimulus; IEA:Ensembl.
GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:BHF-UCL.
GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
GO; GO:0071222; P:cellular response to lipopolysaccharide; IMP:MGI.
GO; GO:0031669; P:cellular response to nutrient levels; IEA:Ensembl.
GO; GO:1990646; P:cellular response to prolactin; IEA:Ensembl.
GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:BHF-UCL.
GO; GO:0050829; P:defense response to Gram-negative bacterium; TAS:BHF-UCL.
GO; GO:0050830; P:defense response to Gram-positive bacterium; TAS:BHF-UCL.
GO; GO:0042832; P:defense response to protozoan; IEA:Ensembl.
GO; GO:0051607; P:defense response to virus; IDA:BHF-UCL.
GO; GO:0031018; P:endocrine pancreas development; ISS:BHF-UCL.
GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; IEA:Ensembl.
GO; GO:0070091; P:glucagon secretion; ISS:BHF-UCL.
GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl.
GO; GO:0002384; P:hepatic immune response; IDA:BHF-UCL.
GO; GO:0006959; P:humoral immune response; IC:BHF-UCL.
GO; GO:0006954; P:inflammatory response; IDA:BHF-UCL.
GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IDA:BHF-UCL.
GO; GO:0031294; P:lymphocyte costimulation; IEA:Ensembl.
GO; GO:0002548; P:monocyte chemotaxis; IC:BHF-UCL.
GO; GO:0046716; P:muscle cell cellular homeostasis; IEA:Ensembl.
GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
GO; GO:0045779; P:negative regulation of bone resorption; ISS:BHF-UCL.
GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
GO; GO:0045079; P:negative regulation of chemokine biosynthetic process; ISS:UniProtKB.
GO; GO:0032966; P:negative regulation of collagen biosynthetic process; IDA:BHF-UCL.
GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
GO; GO:0050710; P:negative regulation of cytokine secretion; IEA:Ensembl.
GO; GO:0045599; P:negative regulation of fat cell differentiation; NAS:BHF-UCL.
GO; GO:0045721; P:negative regulation of gluconeogenesis; IEA:Ensembl.
GO; GO:0046888; P:negative regulation of hormone secretion; IEA:Ensembl.
GO; GO:2000660; P:negative regulation of interleukin-1-mediated signaling pathway; ISS:BHF-UCL.
GO; GO:0010888; P:negative regulation of lipid storage; NAS:BHF-UCL.
GO; GO:0045837; P:negative regulation of membrane potential; IEA:Ensembl.
GO; GO:0048635; P:negative regulation of muscle organ development; IEA:Ensembl.
GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl.
GO; GO:0006469; P:negative regulation of protein kinase activity; IEA:Ensembl.
GO; GO:0031175; P:neuron projection development; IMP:BHF-UCL.
GO; GO:0001781; P:neutrophil apoptotic process; IDA:UniProtKB.
GO; GO:0002446; P:neutrophil mediated immunity; TAS:BHF-UCL.
GO; GO:0030168; P:platelet activation; TAS:BHF-UCL.
GO; GO:0002675; P:positive regulation of acute inflammatory response; IDA:BHF-UCL.
GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
GO; GO:0050871; P:positive regulation of B cell activation; IDA:BHF-UCL.
GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
GO; GO:0071864; P:positive regulation of cell proliferation in bone marrow; IEA:Ensembl.
GO; GO:0032722; P:positive regulation of chemokine production; IDA:BHF-UCL.
GO; GO:0045740; P:positive regulation of DNA replication; IEA:Ensembl.
GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL.
GO; GO:0051024; P:positive regulation of immunoglobulin secretion; IDA:BHF-UCL.
GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
GO; GO:0046427; P:positive regulation of JAK-STAT cascade; IDA:BHF-UCL.
GO; GO:0002690; P:positive regulation of leukocyte chemotaxis; TAS:BHF-UCL.
GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
GO; GO:0045669; P:positive regulation of osteoblast differentiation; TAS:BHF-UCL.
GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:MGI.
GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:MGI.
GO; GO:0033160; P:positive regulation of protein import into nucleus, translocation; IEA:Ensembl.
GO; GO:0051897; P:positive regulation of protein kinase B signaling; IEA:Ensembl.
GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IDA:BHF-UCL.
GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
GO; GO:2000366; P:positive regulation of STAT protein import into nucleus; IC:BHF-UCL.
GO; GO:0042102; P:positive regulation of T cell proliferation; IDA:BHF-UCL.
GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; ISS:BHF-UCL.
GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; IEA:Ensembl.
GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB.
GO; GO:0051971; P:positive regulation of transmission of nerve impulse; IEA:Ensembl.
GO; GO:2000676; P:positive regulation of type B pancreatic cell apoptotic process; TAS:BHF-UCL.
GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IDA:BHF-UCL.
GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
GO; GO:0045765; P:regulation of angiogenesis; IC:BHF-UCL.
GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl.
GO; GO:0045188; P:regulation of circadian sleep/wake cycle, non-REM sleep; IEA:Ensembl.
GO; GO:0010574; P:regulation of vascular endothelial growth factor production; IDA:BHF-UCL.
GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
GO; GO:0010996; P:response to auditory stimulus; IEA:Ensembl.
GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
GO; GO:0009409; P:response to cold; IEA:Ensembl.
GO; GO:0042493; P:response to drug; IEA:Ensembl.
GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
GO; GO:0051384; P:response to glucocorticoid; IDA:BHF-UCL.
GO; GO:0009408; P:response to heat; IEA:Ensembl.
GO; GO:0032868; P:response to insulin; IEA:Ensembl.
GO; GO:0032494; P:response to peptidoglycan; NAS:BHF-UCL.
GO; GO:0001878; P:response to yeast; IEA:Ensembl.
GO; GO:0072540; P:T-helper 17 cell lineage commitment; ISS:UniProtKB.
InterPro; IPR009079; 4_helix_cytokine-like_core.
InterPro; IPR003574; IL-6.
InterPro; IPR030474; IL-6/GCSF/MGF.
InterPro; IPR030473; IL6/GCSF/MGF_CS.
PANTHER; PTHR10078:SF51; PTHR10078:SF51; 1.
Pfam; PF00489; IL6; 1.
PIRSF; PIRSF001935; IL6_MGF_GCSF; 1.
PRINTS; PR00433; IL6GCSFMGF.
SMART; SM00126; IL6; 1.
SUPFAM; SSF47266; SSF47266; 1.
PROSITE; PS00254; INTERLEUKIN_6; 1.
1: Evidence at protein level;
3D-structure; Acute phase; Complete proteome; Cytokine;
Direct protein sequencing; Disulfide bond; Glycoprotein;
Growth factor; Phosphoprotein; Polymorphism; Reference proteome;
Secreted; Signal.
SIGNAL 1 29 {ECO:0000269|PubMed:1883960,
ECO:0000269|PubMed:2610854,
ECO:0000269|PubMed:3279116}.
CHAIN 30 212 Interleukin-6.
/FTId=PRO_0000015582.
MOD_RES 81 81 Phosphoserine; by FAM20C.
{ECO:0000269|PubMed:26091039}.
CARBOHYD 73 73 N-linked (GlcNAc...) asparagine.
{ECO:0000269|PubMed:1883960}.
DISULFID 72 78 {ECO:0000269|PubMed:2472117}.
DISULFID 101 111 {ECO:0000269|PubMed:2472117}.
VARIANT 32 32 P -> S (in dbSNP:rs2069830).
{ECO:0000269|Ref.10}.
/FTId=VAR_013075.
VARIANT 162 162 D -> E (in dbSNP:rs13306435).
/FTId=VAR_029266.
VARIANT 162 162 D -> V (in dbSNP:rs2069860).
{ECO:0000269|Ref.10}.
/FTId=VAR_013076.
MUTAGEN 173 173 A->V: Almost no loss of activity.
{ECO:0000269|PubMed:2037043}.
MUTAGEN 185 185 W->R: No loss of activity.
{ECO:0000269|PubMed:2037043}.
MUTAGEN 204 204 S->P: 87% loss of activity.
{ECO:0000269|PubMed:2037043}.
MUTAGEN 210 210 R->K,E,Q,T,A,P: Loss of activity.
{ECO:0000269|PubMed:2037043}.
MUTAGEN 212 212 M->T,N,S,R: Loss of activity.
{ECO:0000269|PubMed:2037043}.
HELIX 49 75 {ECO:0000244|PDB:1ALU}.
STRAND 76 79 {ECO:0000244|PDB:2IL6}.
TURN 81 83 {ECO:0000244|PDB:4CNI}.
HELIX 84 87 {ECO:0000244|PDB:4CNI}.
HELIX 97 99 {ECO:0000244|PDB:1ALU}.
STRAND 102 105 {ECO:0000244|PDB:4J4L}.
HELIX 108 132 {ECO:0000244|PDB:1ALU}.
STRAND 134 136 {ECO:0000244|PDB:4J4L}.
HELIX 137 157 {ECO:0000244|PDB:1ALU}.
STRAND 159 161 {ECO:0000244|PDB:1ALU}.
HELIX 169 180 {ECO:0000244|PDB:1ALU}.
HELIX 184 209 {ECO:0000244|PDB:1ALU}.
SEQUENCE 212 AA; 23718 MW; 1F1ED1FE1B734079 CRC64;
MNSFSTSAFG PVAFSLGLLL VLPAAFPAPV PPGEDSKDVA APHRQPLTSS ERIDKQIRYI
LDGISALRKE TCNKSNMCES SKEALAENNL NLPKMAEKDG CFQSGFNEET CLVKIITGLL
EFEVYLEYLQ NRFESSEEQA RAVQMSTKVL IQFLQKKAKN LDAITTPDPT TNASLLTKLQ
AQNQWLQDMT THLILRSFKE FLQSSLRALR QM


Related products :

Catalog number Product name Quantity
E0079h ELISA B-cell stimulatory factor 2,BSF-2,CDF,CTL differentiation factor,Homo sapiens,Human,Hybridoma growth factor,IFNB2,IFN-beta-2,IL6,IL-6,Interferon beta-2,Interleukin-6 96T
U0079h CLIA B-cell stimulatory factor 2,BSF-2,CDF,CTL differentiation factor,Homo sapiens,Human,Hybridoma growth factor,IFNB2,IFN-beta-2,IL6,IL-6,Interferon beta-2,Interleukin-6 96T
E0079h ELISA kit B-cell stimulatory factor 2,BSF-2,CDF,CTL differentiation factor,Homo sapiens,Human,Hybridoma growth factor,IFNB2,IFN-beta-2,IL6,IL-6,Interferon beta-2,Interleukin-6 96T
10-663-45216 Interleukin-6 Rat - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 0.002 mg
10-663-45216 Interleukin-6 Rat - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 0.01 mg
10-663-45216 Interleukin-6 Rat - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 1 mg
10-664-50012 Interleukin-6 - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 0.1 mg
10-664-50012 Interleukin-6 - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 0.05 mg
10-663-45083 Interleukin-6 (IL-6) Human - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 0.005 mg
15-288-22495 Interleukin-6 - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF Polyclonal 0.05 mg
15-288-22495 Interleukin-6 - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF Polyclonal 0.1 mg
10-663-45226 Interleukin-6 (IL-6) Porcine - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 0.1 mg
10-663-45181 Interleukin-6 (IL-6) Mouse - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 1 mg
10-663-45226 Interleukin-6 (IL-6) Porcine - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 0.01 mg
10-663-45181 Interleukin-6 (IL-6) Mouse - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 0.01 mg
10-663-45226 Interleukin-6 (IL-6) Porcine - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 0.002 mg
10-663-45181 Interleukin-6 (IL-6) Mouse - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 0.002 mg
10-663-45083 Interleukin-6 (IL-6) Human - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 0.02 mg
10-663-45083 Interleukin-6 (IL-6) Human - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF N_A 1 mg
20-783-72824 RAT ANTI HUMAN INTERLEUKIN-6 - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF Monoclonal 0.5 mg
20-783-72823 RAT ANTI HUMAN INTERLEUKIN-6 - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF Monoclonal 0.5 mg
18-783-78337 RABBIT ANTI HUMAN INTERLEUKIN-6 - IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF Polyclonal 0.1 mg
20-321-175080 INTERLEUKIN-6 (IL-6) - MONOCLONAL ANTIBODY TO HUMAN INTERLEUKIN-6 (IL-6); IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF Monoclon 0.1 mg
20-663-48009 Interleukin-6 (mAHuIL-6) - Mouse Anti Human Interleukin-6 (mAHuIL-6); IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF Monoclonal 1 mg
20-663-48009 Interleukin-6 (mAHuIL-6) - Mouse Anti Human Interleukin-6 (mAHuIL-6); IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF Monoclonal 0.5 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur